Shi Bo, Yang Zhirong, Zhu Yixia, Jiang Chaoming, Yuan Dawu, Zhang Jin
Department of Psychiatry, The Second Hospital of Jinhua, Jinhua, Zhejiang Province, China.
Noro Psikiyatr Ars. 2025 Jun 11;62(2):195-204. doi: 10.29399/npa.28774. eCollection 2025.
This study aimed to investigate the efficacy and safety of blonanserin in patients with schizophrenia.
Electronic databases (PubMed, Web of Science, Cochrane Library, Embase) were searched. Studies evaluating the efficacy and safety of blonanserin in treating schizophrenia were inclued. The combined effect sizes were calculated using relative risk (RR), risk difference (RD) or mean difference (MD).
Overall, 13 prospective studies involving 2,479 patients with schizophrenia were summarised and analysed. We selected five commonly used antipsychotic drugs, namely haloperidol, risperidone, olanzapine, paliperidone and aripiprazole. The meta-analysis showed that compared with a placebo, blonanserin significantly improved the Positive and Negative Syndrome Scale (PANSS) total scores (MD:-7.91; 95% confidence interval [CI]:-15.56, -0.26) and positive scores (MD:-2.48; 95% CI:-4.79, -0.18), and it was comparable with other Antipsychotic drugs regarding PANSS total scores, positive scores and general psychopathology scores. Additionally, the difference between blonanserin and haloperidol (MD:-0.75; 95% CI:-1.00, -0.50) on PANSS negative score changes was statistically significant. At the same time, the safety analysis revealed that compared with risperidone, blonanserin was associated with a lower risk of increased blood prolactin (RR:0.66; 95% CI: 0.51, 0.86), hyperprolactinemia (RR: 0.30; 95% CI: 0.11, 0.78) and weight gain (RD: -0.04; 95% CI: -0.07, -0.01) as well as a higher risk of akathisia (RD: 0.10; 95% CI: 0.04, 0.17). Moreover, it exhibited side-effects similar to those of other antipsychotic drugs regarding constipation, dizziness, headache, insomnia, muscle rigidity and hypersalivation.
Blonanserin is effective and safe in the treatment of schizophrenia, which is beneficial for guiding the clinical practice of schizophrenia treatment. However, more high-quality studies are needed in the future to validate its effect.
本研究旨在探讨布南色林治疗精神分裂症患者的疗效和安全性。
检索电子数据库（PubMed、Web of Science、Cochrane图书馆、Embase）。纳入评估布南色林治疗精神分裂症疗效和安全性的研究。使用相对危险度（RR）、风险差值（RD）或均数差值（MD）计算合并效应量。
总体而言，总结并分析了13项涉及2479例精神分裂症患者的前瞻性研究。我们选择了五种常用抗精神病药物，即氟哌啶醇、利培酮、奥氮平、帕利哌酮和阿立哌唑。荟萃分析表明，与安慰剂相比，布南色林显著改善阳性和阴性症状量表（PANSS）总分（MD：-7.91；95%置信区间[CI]：-15.56，-0.26）和阳性得分（MD：-2.48；95%CI：-4.79，-0.18），并且在PANSS总分、阳性得分和一般精神病理学得分方面与其他抗精神病药物相当。此外，布南色林和氟哌啶醇在PANSS阴性得分变化上的差异（MD：-0.75；95%CI：-1.00，-0.50）具有统计学意义。同时，安全性分析显示，与利培酮相比，布南色林导致血催乳素升高（RR：0.66；95%CI：0.51，0.86）、高催乳素血症（RR：0.30；95%CI：0.11，0.78）和体重增加（RD：-0.04；95%CI：-0.07，-0.01）的风险较低，而静坐不能风险较高（RD：0.10；95%CI：0.04，0.17）。此外，在便秘、头晕、头痛、失眠、肌肉强直和流涎过多方面，其副作用与其他抗精神病药物相似。
布南色林治疗精神分裂症有效且安全，这有助于指导精神分裂症治疗的临床实践。然而，未来需要更多高质量研究来验证其效果。
